Back to News
Market Impact: 0.2
Cellyan Plans 1-For-20 Reverse Stock Split To Regain Nasdaq Compliance; Shares Down
Source: Nasdaq
Company Fundamentals
Cellyan Biotechnology said it plans a board-approved 1-for-20 reverse stock split. The article provides no effective date or further details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
HKPD-0.20
More News
- The U.S. market has never been more focused on one single bet—but AI’s payoff will likely take decades
- Meta put out an ambitious roadmap to Muse monetization after strong quarter and guide
- CoreWeave’s market confidence erodes as bond yields spike and stock sinks
- Why is Tesla stock falling after-hours today?
- Meta ordered to pay $25 billion in case related to Cambridge Analytica scandal
- Zuckerberg told Meta directors he might leave California, where he could lose billions to a wealth tax. Meta answered with a new class of stock